APPxPS1 model
Take advantage of InnoSer’s expanded neurology CRO services spanning new Alzheimer’s in vivo research models and expertise
Key characteristics
- Progressive β-amyloid plaque development in cortex, hippocampus and subiculum from an age of 6 months onwards
- Pyroglutamate-modified Aβ42 (Aβ3(pE)-42) is detected in the insoluble brain fraction from 7 months onwards
- Progressive microgliosis and astrocytosis from an age of 6 months
- Cognitive impairment in the Morris water maze paradigm from an age 5 months and hippocampal LTP deficit at 8 months (not tested earlier)
- CAA pathology and micro-bleedings from 8 and 12-15 months of age, respectively
Progressive total plaque load (an anti-Aβ antibody) and dense plaque load (Thioflavin S) in the subiculum as measured by IHC (mean ± SEM, N = 10).
Data from a study (Easton et al., 2013) that showed a significant improvement in reference memory in APPxPS1 mice along with a dose-dependent reduction in brain Aβ. These results suggest that donepezil may alleviate cognitive impairments in Alzheimer’s disease, in part, by reducing brain Aβ.
Literature
Describing papers:
Therapeutic intervention papers:
- Easton et al., 2013: Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease. DOI: 10.1007/s00213-013-3152-3
- Hansen et al., 2016: Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease. DOI: https://pubmed.ncbi.nlm.nih.gov/27421117/
- Latta-Mahieu et al., 2017: Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-b burden in several amyloid transgenic mouse models. DOI: 10.1002/glia.23260
Services
Don’t See Your Model? We Can Help!
Our experts specialize in tailored solutions to meet your unique research needs. Let’s discuss how we can support your project.
Elevate Your Research With Additional Services
Readouts & Analyses
- Full suite of histopathology services
- Immunohistochemistry of brain and nerve tissues (IHC)
- Bioanalyses in various biological matrices
- Flow Cytometry
- ELISA, Ultra-Sensitive ELISA for CSF/plasma biomarkers
- Meso Scale Discovery (MSD)
- Immunoblotting
In Vivo Analyses
- Mouse breeding and genotyping
- Microbiome transplantation studies
- Compound administration
- Stereotaxic surgery
- EEG, EMG and ECG analyses
- Cannula implantation
- Tissue collection and analysis
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com